Twist Bioscience Corporation

TWST

CIK 0001581280 · Quarterly mode · latest period FY2025 (Q4) (ending 2025-12-31) · sourced from SEC EDGAR

At a glance · FY2025 (Q4)

Revenue
$104M
↑+16.9% +$15Mvs FY2024 (Q4)
Gross Profit
$54M
↑+26.0% +$11Mvs FY2024 (Q4)

Quality Score

Quality score

6-dimension fundamental snapshot · latest annual filed values · S&P 500 calibration

Strong
67/100
  • Profitability
    0ROIC -22.8% (10% = solid, 20%+ = moat)
  • Liquidity
    100Current Ratio 3.64 (above 1.5 = solid)
  • Leverage
    100D/E 0.00 (under 0.5 = conservative)
  • Efficiency
    31Asset Turnover 0.60x (1.0+ = capital-efficient)
  • Growth
    73Revenue YoY +16.9% (10% = solid, 25%+ = elite)
  • Margin Trend
    100Op Margin -31.7% · trend +35.1pts (4Q avg vs prior 4Q)

Calibrated to S&P 500 medians. Each sub-score is computed from a single CFA-grade ratio (Profitability = ROIC, Liquidity = Current Ratio, Leverage = D/E, Efficiency = Asset Turnover, Growth = Revenue YoY, Margin Trend = 4Q operating-margin avg vs prior 4Q). Overall = simple mean.

Capital allocation · trailing 4 quarters

how the company spent its cash
Capex (TTM)
$36M
investment in PP&E
Stock-based comp (TTM)
$66M
non-cash dilution

Balance sheet · 2025-12-31

latest filed snapshot
Total assets
$638M
everything owned
Total liabilities
$182M
everything owed
Stockholders' equity
$456M
shareholder claim
Net debt
$-148M
Net cash position ($148M)

Recent performance · 34 quarters

Revenue↑+16.9% +$15M
$104M
Net Income↑+3.4% +$1M
$-31M
Free Cash Flow↓-46.8% -$11M
$-35M
Operating Margin↑+7.3pts
-31.7%

Drill down